跳至主要內容
MediHelp
MediHelp 藥品參考

藥品參考

Mavacamten

Mavacamten is a medicine in the class cardiovascular.

  • 藥物類別: Cardiovascular

最後更新 來源: US FDA label

僅供醫療專業人員參考。本頁為簡要摘要，並非醫療建議，亦不能取代官方仿單或臨床判斷。開立處方或調劑前請務必核實。

本頁的臨床內容僅提供英文版。

重點資訊

藥物類別
Cardiovascular
常見劑型
膠囊
已知交互作用
108 (禁忌併用: 20 · 嚴重: 45 · 中度: 29 · 輕微: 14)
商品名
2
國家與市場
2

劑型、規格與商品名稱會因國家而異。請核對您手上的產品。

作用方式

Allosteric, reversible inhibitor selective for cardiac myosin; reduces the number of myosin heads entering power-generating states, lowering systolic and residual diastolic cross-bridge formation, reducing dynamic LVOT obstruction and improving filling pressures.

成人常用劑量（仿單摘要）

Symptomatic NYHA class II-III obstructive HCM: starting dose 5 mg orally once daily without regard to food; titrate among 2.5 mg, 5 mg, 10 mg or 15 mg once daily; maximum 15 mg once daily

僅摘錄仿單中第一行劑量說明；完整的劑量內容請見 App。

懷孕與哺乳

懷孕
Unsafe May cause fetal harm based on animal data; no human data. Effective contraception during treatment and for 4 months after last dose.
哺乳
Unknown Presence in milk, effects on infant and milk production are unknown; weigh benefits of breastfeeding against maternal need.

已通報的副作用

  • Dizziness
  • Syncope

黑框警語

  • Reduces LVEF and can cause heart failure from systolic dysfunction. Echocardiographic LVEF assessment required before and during treatment. Do not initiate if LVEF <55%; interrupt if LVEF <50% or heart failure symptoms or worsening clinical status. Strong CYP2C19 inhibitors and moderate to strong CYP2C19 or CYP3A4 inducers are contraindicated. Available only through the CAMZYOS REMS Program.

禁忌症

  • Concomitant strong CYP2C19 inhibitors
  • Concomitant moderate to strong CYP2C19 inducers or moderate to strong CYP3A4 inducers

哪些人需要特別留意

  • Heart failure risk higher with serious intercurrent illness or arrhythmia; assess clinical status and LVEF regularly.
  • CYP450 interactions may cause heart failure or loss of effectiveness, including with OTC omeprazole, esomeprazole, cimetidine.
  • Available only via REMS program; prescribers, patients and pharmacies must be certified/enrolled.

請告知藥師或醫師您是否懷孕或哺乳、是否患有腎臟或肝臟疾病、是否有過敏，以及您正在使用的所有其他藥物或保健品。

重要交互作用 (108)

All 108 interactions, with severity and what to do

Pro+ 會員專屬

解鎖完整頁面

建立帳號並開始 Pro+ 試用，即可開啟 Mavacamten 的完整藥品專論：劑量、懷孕與哺乳、副作用、警示及所有交互作用。

  • Dosing by age, kidney and liver function, and further dose lines
  • Renal and hepatic dose adjustments
  • How to give it
  • Pharmacokinetics
  • Patient counselling points
  • Food interactions
建立免費帳號 登入

在網頁版免費試用 Pro+ 14 天，無需信用卡。

常見問題

What is Mavacamten used for?

Mavacamten is a medicine in the class cardiovascular.

What side effects have been reported with Mavacamten?

Dizziness, Syncope. Serious warning: Reduces LVEF and can cause heart failure from systolic dysfunction.

Can Mavacamten be taken in pregnancy or while breastfeeding?

Pregnancy: Unsafe. May cause fetal harm based on animal data; no human data. Effective contraception during treatment and for 4 months after last dose. Breastfeeding: Unknown. Presence in milk, effects on infant and milk production are unknown; weigh benefits of breastfeeding against maternal need.

What does Mavacamten interact with?

MediHelp lists 108 known interactions for Mavacamten. Contraindicated: 20 · Major: 45 · Moderate: 29 · Minor: 14. The most serious include Apalutamide, Carbamazepine, Clarithromycin.

在 MediHelp App 中取得完整藥品專論、劑量資訊與交互作用檢查

在 MediHelp App 中開啟完整參考資料、檢查多種藥物間的交互作用，並使用劑量工具。

下載於App Store 立即下載Google Play

依 A–Z 瀏覽 · 藥品參考

取得 App 登入